Sector: Health Care
Director information for INSMED INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Carol A. Schafer | Director | 62 | ["more than 30 years of experience in investment banking, corporate finance and business development", "significant experience in financing and equity capital markets in the pharmaceutical and biotechnology industries", "recent cybersecurity training"] | ["Audit", "Compensation", "Audit Committee", "Nominations and Governance Committee"] | 2026 |
| Clarissa Desjardins, Ph.D. | Director | 59 | ["More than 30 years of leadership experience in biotechnology, pharmaceuticals, and research", "Unique experience in the founding of several pharmaceutical and biotechnology companies", "Leadership roles", "Corporate development expertise", "Public company experience", "Medical education"] | ["Chair of the Science and Technology Committee"] | 2026 |
| David R. Brennan | Lead Independent Director | 72 | ["More than 50 years of experience in the pharmaceutical industry", "Experience at public pharmaceutical companies", "Board experience and roles in executive management, commercialization, and product management"] | ["Compensation", "Chair of the Compensation Committee"] | 2026 |
| David W.J. McGirr | Director | 71 | [] | ["Compensation"] | 2026 |
| Dr. Desjardins | Chair | [] | ["Science and Technology Committee"] | 2026 | |
| Dr. Sharoky | [] | ["Nominations and Governance Committee", "Science and Technology Committee"] | 2026 | ||
| Elizabeth McKee Anderson | Director; Chair | 68 | ["More than 30 years of leadership in biotechnology, pharmaceuticals, and vaccines", "Extensive global marketing and infectious disease experience"] | ["Audit", "Compensation", "Chair of the Nominations and Governance Committee", "Member of the Audit Committee", "Nominations and Governance Committee"] | 2026 |
| Leo Lee | Non-Executive Director | 56 | ["More than 25 years of experience in the Pharma industry in Japan", "Experience in commercial leadership roles in Japan and the Asia Pacific region", "President of China (2024 - present)", "President of Japan (2020 - 2024)", "Non-Executive Director of Regeneus", "CEO of Regeneus (2019 \u2013 2020)", "President of Japan at Merck KGaA", "President of Japan at Allergan plc", "Vice President of Sales at Merck & Co.", "General Manager at IQVIA", "Senior Director of Western Regional Sales at Accelrys, Inc."] | ["Audit", "Compensation", "Compensation Committee", "Science and Technology Committee"] | 2026 |
| Martina Flammer | Chief Medical Officer | ["More than 25 years in medical and commercial roles in biotechnology and pharmaceutical industry", "Former Senior Vice President at Boehringer Ingelheim", "Various positions at Boehringer Ingelheim from 2012 to 2018", "Roles at Pfizer, Inc. from 2000 to 2011", "MBA from New York University Stern School of Business", "M.D. from University of Vienna Medical School"] | [] | 2026 | |
| Martina Flammer, M.D. | Chief Medical Officer | 62 | ["Leading global clinical development", "Clinical operations", "Regulatory affairs", "Drug safety", "Pharmacovigilance", "Medical affairs"] | [] | 2026 |
| Melvin Sharoky, M.D. | Director; Chairman From:June 2009 - December 2010 | 75 | ["More than 35 years of experience in the pharmaceutical industry", "Medical experience as a physician", "Background as an executive of pharmaceutical companies", "Public company board service", "Senior management experience", "Leadership experience", "Financial and strategic planning experience"] | ["Compensation", "Nominations and Governance Committee", "Science and Technology Committee"] | 2026 |
| Sara Bonstein | Chief Financial Officer | 45 | ["25 years of operational and financial leadership in the life sciences industry", "Former Chief Financial Officer for several public biotech companies", "Experience at Eli Lilly and Company in various roles", "Experience at ImClone Systems in various roles", "Experience at Johnson & Johnson in various roles", "MBA from Rider University", "Bachelor of Science in Finance from The College of New Jersey", "Managing financial activities", "Financial reporting", "Financial planning and analysis", "Treasury", "Accounting", "Tax", "Investor relations"] | [] | 2026 |
| William H. Lewis | Director; Chair of the Board; Chair and CEO; Chair and Chief Executive Officer | 57 | ["20 years of executive experience in the life sciences industry", "30 years of experience in the pharmaceutical and finance industries", "Pivotal role in re-orienting Aegerion's strategy", "Experience with financing, orphan drug development and commercialization", "International business development", "Responsible for corporate strategy", "Provides direction and leadership", "Developing corporate mission and objectives", "Providing direction and leadership", "Leading U.S. commercial organization"] | [] | 2026 |
